Value of serial carcinoembryonic antigen levels in patients with resectable adenocarcinoma of the esophagus and stomach
Authors:
Open Access
Abstract
Background. Adenocarcinomas of the esophagus and the stomach are highly virulent and remain a major health problem worldwide; 5‐year survival rates have not changed in the past 30 years. Recently, preoperative chemotherapy has been used to treat these adenocarcinomas. The authors evaluated the usefulness of serial serum carcinoembryonic antigen (CEA) levels in diagnosing these patients and compared the prognosis of patients with high or normal CEA levels. Methods. Ninety consecutive patients with potentially resectable adenocarcinoma of the esophagus or stomach treated with preoperative chemotherapy were evaluated. Serum CEA levels were determined before registration, after each chemotherapy course, every 3 months for the first year after completion of all therapy, and every 6 months thereafter for 5 years. Results. The CEA positivity rate before chemotherapy was 22.2% (20/90); after chemotherapy, it dropped to 10.9% (9/82). An increasing CEA level predicted relapse and correlated well with liver, lung, or pleural involvement in some patients. Most patients with peritoneal involvement did not show elevated levels of CEA. Clinical responses correlated with declining levels of CEA in the patients who showed a negative conversion in CEA level after chemotherapy. Conclusions. An elevated serum CEA level enabled early detection of relapse in the absence of clinical symptoms in patients with adenocarcinoma of the esophagus or the stomach. The level of CEA was also useful in monitoring the response to chemotherapy in patients who had a high CEA level before treatment. Although the pre‐ and postchemotherapy CEA‐positive group had a higher relapse rate than that of other group, the CEA level did not predict resectability or survival. Future research with labeled monoclonal anti‐CEA antibodies may prove useful for certain groups of patients. Cancer 1995;75:451‐6.Keywords
This publication has 24 references indexed in Scilit:
- Cancer statistics, 1994CA: A Cancer Journal for Clinicians, 1994
- Adenocarcinoma of the Stomach: Are We Making Any Progress?Southern Medical Journal, 1987
- Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern cooperative oncology group study (EST 3275)Cancer, 1985
- Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A veterans administration surgical oncology group reportCancer, 1983
- Gastric CarcinomaAnnals of Surgery, 1983
- Surgical Treatment of Carcinoma of the Esophagus and Cardiac Portion of the Stomach in 850 PatientsThe Annals of Thoracic Surgery, 1983
- Adenocarcinoma of the stomach: Current results of treatmentCancer, 1983
- Controlled trial of adjuvant chemotherapy following curative resection for gastric cancerCancer, 1982
- Treatment of Carcinoma of the Esophagus Retrospective Study of 2,400 PatientsAnnals of Surgery, 1980
- Review of Consecutive Ten Year IntervalsAnnals of Surgery, 1979